GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...
The news followed an investigation by POLITICO’s E&E News into climate-friendly inhalers and how drug giants are developing them to undermine competition. The pharmaceutical giant AstraZeneca ...
Flovent HFA, GSK’s brand name for its discontinued inhaler, hasn’t been available since December 2023 when, in response to new federal price limits, the company introduced an essentially ...
Dec 9 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple ...
LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...
Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...
Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we ...
The inhalers tested at temperatures outside ... NJ) and Ventolin HFA (GlaxoSmithKline, Research Triangle Park, NC). These products contain albuterol as an active ingredient and use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results